Screener
Aclaris Therapeutics ACRS Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
FAQ
- What is Aclaris Therapeutics's accounts payable?
- Aclaris Therapeutics (ACRS) reported accounts payable of $15.52M in Q2 2026.
- How has Aclaris Therapeutics's accounts payable changed year-over-year?
- Aclaris Therapeutics's accounts payable increased by 76.4% year-over-year, from $8.8M to $15.52M.
- What is the long-term trend for Aclaris Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), Aclaris Therapeutics's accounts payable has grown at a 20.2% compound annual growth rate (CAGR), from $5.25M to $13.16M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Aclaris Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude